Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Mok, Tony
Wu, Yi-Long
Watson, Patricia A.
Zhang, Jin
Rangwala, Reshma A.
Lopes, Gilberto
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Soc Clin Oncol, Guangzhou, Guangdong, Peoples R China
[3] IASLC, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[5] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Ctr Paulista Oncol & HCor Onco, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8105
引用
收藏
页数：1
相关论文
共 50 条
  • [21] KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC
    Kubota, Kaoru
    Cho, Byoung Chul
    Srimuninnimit, Vichien
    Fan, Yu
    Zhou, Jianying
    Zhang, Li
    Zhou, Qing
    Hosomi, Yukio
    Takeoka, Hiroaki
    Mukherjee, Rinee
    Fu, Wei
    Souza, Fabricio
    Mok, Tony S. K.
    Zhang, Li
    ANNALS OF ONCOLOGY, 2022, 33 : S472 - S472
  • [22] KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
    de Castro, Gilberto
    Kudaba, Iveta
    Wu, Yi-Long
    Lopes, Gilberto
    Kowalski, Dariusz M.
    Turna, Hande Z.
    Caglevic, Christian
    Zhang, Li
    Karaszewska, Boguslawa
    Laktionov, Konstantin K.
    Srimuninnimit, Vichien
    Bondarenko, Igor
    Kubota, Kaoru
    Mukherjee, Rinee
    Lin, Jianxin
    Souza, Fabricio
    Mok, Tony S. K.
    Cho, Byoung Chul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A390 - A390
  • [23] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
    Mok, Tony S. K.
    Wu, Yi-Long
    Kudaba, Iveta
    Kowalski, Dariusz M.
    Cho, Byoung Chul
    Turna, Hande Z.
    Castro, Gilberto, Jr.
    Srimuninnimit, Vichien
    Laktionov, Konstantin K.
    Bondarenko, Igor
    Kubota, Kaoru
    Lubiniecki, Gregory M.
    Zhang, Jin
    Kush, Debra
    Lopes, Gilberto
    LANCET, 2019, 393 (10183): : 1819 - 1830
  • [24] Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Balmanoukian, A. S.
    Rizvi, N. A.
    Garon, E. B.
    Patnaik, A.
    Gandhi, L.
    Leighl, N. B.
    Goldman, J. W.
    Eder, J. P.
    Johnson, E. A.
    Blumenschein, G. R.
    Gubens, M. A.
    Papadopoulos, K. P.
    Lubiniecki, G. M.
    Zhang, J.
    Niewood, M.
    Emancipator, K.
    Dolled-Filhart, M.
    Hanson, M. E.
    Hui, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S1 - S2
  • [25] Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Rizvi, Naiyer A.
    Garon, Edward B.
    Patnaik, Amita
    Gandhi, Leena
    Leighl, Natasha B.
    Balmanoukian, Ani Sarkis
    Goldman, Jonathan Wade
    Eder, Joseph Paul
    Johnson, Elizabeth
    Blumenschein, George R.
    Gubens, Matthew A.
    Papadopoulos, Kyriakos P.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Niewood, Michelle
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Hanson, Mary Elizabeth
    Hui, Rina
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?
    Gridelli, Cesare
    Sgambato, Assunta
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [27] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    Herbst, Roy S.
    Baas, Paul
    Kim, Dong-Wan
    Felip, Enriqueta
    Perez-Gracia, Jose L.
    Han, Ji-Youn
    Molina, Julian
    Kim, Joo-Hang
    Arvis, Catherine Dubos
    Ahn, Myung-Ju
    Majem, Margarita
    Fidler, Mary J.
    de Castro, Gilberto, Jr.
    Garrido, Marcelo
    Lubiniecki, Gregory M.
    Shentu, Yue
    Im, Ellie
    Dolled-Filhart, Marisa
    Garon, Edward B.
    LANCET, 2016, 387 (10027): : 1540 - 1550
  • [28] Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
    Cho, Byoung Chul
    Lopes, Gilberto
    Kowalski, Dariusz M.
    Kasahara, Kazuo
    Wu, Yi-Long
    Castro, Gilberto
    Turna, Hande Z.
    Cristescu, Razvan
    Aurora-Garg, Deepti
    Loboda, Andrey
    Lunceford, Jared
    Kobie, Julie
    Ayers, Mark
    Pietanza, M. Catherine
    Piperdi, Bilal
    Mok, Tony S.
    CANCER RESEARCH, 2020, 80 (16)
  • [29] Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
    Patnaik, Amita
    Socinski, Mark A.
    Gubens, Matthew A.
    Gandhi, Leena
    Stevenson, James
    Bachman, Robert D.
    Bourque, Jennifer
    Ge, Joy Yang
    Im, Ellie
    Gadgeel, Shirish M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
    Herbst, R. S.
    Lopes, G.
    Kowalski, D. M.
    Kasahara, K.
    Wu, Y-L.
    De Castro, G., Jr.
    Cho, B. C.
    Turna, H. Z.
    Cristescu, R.
    Aurora-Garg, D.
    Lunceford, J.
    Kobie, J.
    Ayers, M.
    Pietanza, M. C.
    Piperdi, B.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2019, 30
12345